Magnetic Nanosystem for Cancer Therapy Using Oncocalyxone A, an Antitomour Secondary Metabolite Isolated from a Brazilian Plant

This paper describes the investigation and development of a novel magnetic drug delivery nanosystem (labeled as MO-20) for cancer therapy. The drug employed was oncocalyxone A (onco A), which was isolated from Auxemma oncocalyx, an endemic Brazilian plant. It has a series of pharmacological properties: antioxidant, cytotoxic, analgesic, anti-inflammatory, antitumor and antiplatelet. Onco A was associated with magnetite nanoparticles in order to obtain magnetic properties. The components of MO-20 were characterized by XRD, FTIR, TGA, TEM and Magnetization curves. The MO-20 presented a size of about 30 nm and globular morphology. In addition, drug releasing experiments were performed, where it was observed the presence of the anomalous transport. The results found in this work showed the potential of onco A for future applications of the MO-20 as a new magnetic drug release nanosystem for cancer treatment.

[1]  P. Doraiswamy,et al.  Metals in our minds: therapeutic implications for neurodegenerative disorders , 2004, The Lancet Neurology.

[2]  L. Deng,et al.  Fabrication of cyclodextrin-functionalized superparamagnetic Fe3O4/amino-silane core–shell nanoparticles via layer-by-layer method , 2009 .

[3]  E. Silveira,et al.  Novel Cordiachromes Isolated from Auxemma oncocalyx , 1993 .

[4]  M. Abrashev,et al.  Raman spectroscopy investigation of magnetite nanoparticles in ferrofluids , 2010 .

[5]  Bikram Singh,et al.  Development of biodegradable nanoparticles for delivery of quercetin. , 2010, Colloids and surfaces. B, Biointerfaces.

[6]  N. Peppas,et al.  Mechanisms of solute release from porous hydrophilic polymers , 1983 .

[7]  Yuanhua Lin,et al.  Synthesis of Fe3O4 Nanoparticles and their Magnetic Properties , 2012 .

[8]  T. P. Braga,et al.  Magnetic composites based on hybrid spheres of aluminum oxide and superparamagnetic nanoparticles of iron oxides , 2010 .

[9]  C. Booth,et al.  Triad sequence assignment of the 13C-NMR spectra of copolymers of ethylene oxide and 1,2-butylene oxide , 1990 .

[10]  D. Leslie-Pelecky,et al.  Iron oxide nanoparticles for sustained delivery of anticancer agents. , 2005, Molecular pharmaceutics.

[11]  E. Lai,et al.  A comparative study of magnetic transferability of superparamagnetic nanoparticles , 2010 .

[12]  A. Curtis,et al.  Surface modified superparamagnetic nanoparticles for drug delivery: Interaction studies with human fibroblasts in culture , 2004, Journal of materials science. Materials in medicine.

[13]  R. R. Huruta,et al.  Oncocalyxones A and C, 1,4-anthracenediones from Auxemma oncocalyx: comparison with anticancer 1,9-anthracenediones. , 2000, Anticancer research.

[14]  L. Costa-Lotufo,et al.  Toxicity to sea urchin egg development of the quinone fraction obtained from Auxemma oncocalyx. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[15]  P A Voltairas,et al.  Hydrodynamics of magnetic drug targeting. , 2002, Journal of biomechanics.

[16]  L. Carbone,et al.  Novel ferrofluids coated with a renewable material obtained from cashew nut shell liquid , 2012 .

[17]  M. Schattner,et al.  Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibα glycoprotein , 2008, British journal of pharmacology.

[18]  Y. Wang,et al.  Formulation of Superparamagnetic Iron Oxides by Nanoparticles of Biodegradable Polymers for Magnetic Resonance Imaging , 2008 .

[19]  K. Neoh,et al.  Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. , 2006, Biomaterials.

[20]  Carla Lopes,et al.  Formas farmacêuticas de liberação modificada: polímeros hidrifílicos , 2005 .

[21]  H. S. dos Santos,et al.  Anthracene derivatives from Auxemma oncocalyx. , 2000, Phytochemistry.

[22]  O. Pessoa,et al.  Analgesic and anti-inflammatory activities of a fraction rich in oncocalyxone A isolated from Auxemma oncocalyx. , 2004, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[23]  T. Higuchi,et al.  Rate of release of medicaments from ointment bases containing drugs in suspension. , 1961, Journal of pharmaceutical sciences.

[24]  Sungho Jin,et al.  Magnetic nanoparticles for theragnostics. , 2009, Advanced drug delivery reviews.

[25]  C. Robic,et al.  Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. , 2008, Chemical reviews.

[26]  V. Bulmus,et al.  The design and utility of polymer-stabilized iron-oxide nanoparticles for nanomedicine applications , 2010 .

[27]  Piero Baglioni,et al.  Magnetoliposomes for controlled drug release in the presence of low-frequency magnetic field , 2010 .

[28]  V. John,et al.  Colloidal drug carries from (sub)micron hyaluronic acid hydrogel particles with tunable properties for biomedical applications , 2010 .

[29]  S. Mazzetto,et al.  Magnetic nanoparticles for a new drug delivery system to control quercetin releasing for cancer chemotherapy , 2011 .

[30]  Christoph Alexiou,et al.  Targeting cancer cells: magnetic nanoparticles as drug carriers , 2006, European Biophysics Journal.

[31]  K. Nakatsuka,et al.  Mixed spinel structure in nanocrystalline NiFe 2 O 4 , 2001 .

[32]  A. Leyva,et al.  Antiproliferative effects of compounds derived from plants of Northeast Brazil , 2000, Phytotherapy research : PTR.

[33]  Pallab Pradhan,et al.  Synthesis and characterizations of water-based ferrofluids of substituted ferrites [Fe1−xBxFe2O4, B=Mn, Co (x=0–1)] for biomedical applications , 2008 .

[34]  Hong Yuan,et al.  Magnetic lipid nanoparticles loading doxorubicin for intracellular delivery: Preparation and characteristics , 2011 .

[35]  C. Booth,et al.  Micellisation of diblock copoly(oxyethylene/oxybutylene) in aqueous solution , 1993 .

[36]  O. Pessoa.  Cordiachromes from Auxemma oncocalyx , 1995 .

[37]  Rui Manadas,et al.  A dissolução in vitro na previsão da absorção oral de fármacos em formas farmacêuticas de liberação modificada , 2002 .